News Releases

Keyword Search

Jan-04-2023
Oncternal Therapeutics Announces the Appointment of Jill DeSimone to the Board of Directors
Jan-03-2023
Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Dec-10-2022
Oncternal Therapeutics Presents Updated Interim Data for Zilovertamab in Combination with Ibrutinib at ASH 2022
Dec-01-2022
Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Nov-14-2022
Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Nov-03-2022
Oncternal Therapeutics Provides Business Update and Announces Third Quarter 2022 Financial Results
Nov-03-2022
Oncternal Therapeutics to Present Updated Interim Phase 1/2 Data for Zilovertamab in Combination with Ibrutinib in an Oral Session at ASH 2022
Oct-27-2022
Oncternal Therapeutics to Provide Business Update and Report Third Quarter 2022 Financial Results
Oct-03-2022
Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Oct-03-2022
Oncternal Therapeutics Receives IND Clearance for ONCT-808, its autologous CAR T Product Candidate Targeting ROR1 for the Treatment of Aggressive B Cell Lymphoma